[{"uuid": "52aae86c-4d7c-35d7-81b3-876ca20bab1c", "title": "CRL Gears Up for Q4 Earnings: Here's What You Need to Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/crl-gears-q4-earnings-heres-124400066.html", "providerPublishTime": 1738586640, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XZlfIZsWv4Zk8B16YMQW3g--~B/aD0zNjA7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37", "width": 620, "height": 360, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/basziZN2oibsd7YoTsUvFQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "2e817115-a3dd-3620-ab3f-db1c813b42ce", "title": "Here are January\u2019s best and worst stocks \u2014 and what may lie ahead for them", "publisher": "MarketWatch", "link": "https://finance.yahoo.com/m/2e817115-a3dd-3620-ab3f-db1c813b42ce/here-are-january%E2%80%99s-best-and.html", "providerPublishTime": 1738540740, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HaZVQ2qCUGhrucSb8.skZA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch_hosted_869/2f30c06fb44fec8947b7b3a9c0a34591", "width": 1280, "height": 640, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tScNywJBSlVof2Vtd6OyfQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch_hosted_869/2f30c06fb44fec8947b7b3a9c0a34591", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["^GSPC", "NVDA", "GE", "META"]}, {"uuid": "5dbe6589-476f-3bc8-a7d3-c4d872d2f7b8", "title": "Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/charles-river-laboratories-schedules-fourth-213000773.html", "providerPublishTime": 1738099800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/QtlQD3b9Hax23QxzWnOioA--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d48325d2083e70b8069d536269fbe5b2", "width": 1245, "height": 326, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/reKHh1IuNZhorRgsogqRrw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d48325d2083e70b8069d536269fbe5b2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "d2856b96-cc89-3fe5-a84d-3334075aa12a", "title": "Sage rejects Biogen\u2019s $469m takeover bid", "publisher": "Pharmaceutical Technology", "link": "https://finance.yahoo.com/m/d2856b96-cc89-3fe5-a84d-3334075aa12a/sage-rejects-biogen%E2%80%99s-%24469m.html", "providerPublishTime": 1738067292, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/TGu_Kz5BSP_UAvpSm5p54w--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/d6bcb48bb145c1e9295bcf183efe7df3", "width": 1024, "height": 576, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/g.VLYJeEg6U7BWPNkV427g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/d6bcb48bb145c1e9295bcf183efe7df3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SAGE", "BIIB"]}, {"uuid": "de66fba0-c5e0-34a4-b104-ee799a160524", "title": "Charles River Launches Apollo for CRADL to Boost Research, Stock Rises", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/charles-river-launches-apollo-cradl-131900050.html", "providerPublishTime": 1737551940, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/U5YlhffUr8O4Y.ygF6AjOw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL", "HAE"]}, {"uuid": "45928906-eb0f-3986-b2df-97961054b989", "title": "Charles River downgraded to Market Perform from Outperform at William Blair", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/charles-river-downgraded-market-perform-121606253.html", "providerPublishTime": 1737634566, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/JAkd0u.p7aqm9cNkwT3ICg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/noN3BfKp3iIZZgFc7RdX4A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CRL"]}, {"uuid": "b7c7a60e-cb36-36ce-be3b-dcbf22c5e6a0", "title": "Goldman Sachs Adjusts Charles River Laboratories International Price Target to $190 From $220, Maintains Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/goldman-sachs-adjusts-charles-river-135340054.html", "providerPublishTime": 1737640420, "type": "STORY", "relatedTickers": ["CRL"]}, {"uuid": "63d9f558-a994-3d6a-8d72-1707f73c5152", "title": "Outlook Therapeutics\u00ae Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/outlook-therapeutics-announces-presentation-efficacy-140500066.html", "providerPublishTime": 1737641100, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/y4uDmJyHk2KbjwlWQIRgEw--~B/aD0zODU7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c3145a8faa5cf425983be7cac2c88e36", "width": 320, "height": 385, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1XEd5V1V8W1pqLXukP_vFQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c3145a8faa5cf425983be7cac2c88e36", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["OTLK"]}, {"uuid": "1b2f406e-de19-3383-8f18-a36d4703f5d5", "title": "William Blair Downgrades Charles River Laboratories International to Market Perform From Outperform", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/william-blair-downgrades-charles-river-121130094.html", "providerPublishTime": 1737547890, "type": "STORY", "relatedTickers": ["CRL"]}, {"uuid": "45adc039-535a-347e-9252-8c4eb71c32b8", "title": "Atara\u2019s T cell programmes hit with clinical hold after third-party site woes", "publisher": "Pharmaceutical Technology", "link": "https://finance.yahoo.com/m/45adc039-535a-347e-9252-8c4eb71c32b8/atara%E2%80%99s-t-cell-programmes-hit.html", "providerPublishTime": 1737549911, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/93DkqpNuPkYUeawv7TBt1g--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/2c9e1b87f2d40b7d36cb768a02937579", "width": 1000, "height": 667, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4A.07QWNtYYe0RowmiIx1g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/2c9e1b87f2d40b7d36cb768a02937579", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GLDAF"]}, {"uuid": "d44307aa-b04e-3737-abff-d9cc00b158dc", "title": "DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/diagnamed-terravent-announce-strategic-collaboration-130000990.html", "providerPublishTime": 1737550800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/8vzhJSjXifKX8eydamHuqA--~B/aD01MDA7dz05NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/eb928c836c33d236c084fa2ae27122c6", "width": 940, "height": 500, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4g9Mh8kE80EMoYkbDNmHcA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/eb928c836c33d236c084fa2ae27122c6", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DGNMF"]}, {"uuid": "6718e427-b1fe-3b52-9551-70d74ba7fa6d", "title": "TD Cowen Adjusts Charles River Laboratories International Price Target to $182 From $227", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/td-cowen-adjusts-charles-river-144258958.html", "providerPublishTime": 1737470578, "type": "STORY", "relatedTickers": ["CRL"]}]